Takeda
Registry sponsor category
Industry
- Company name
- Takeda
- Organisation type
- Industry
- Registered legal name
- Leiras Oy
- Registry sponsor category
- Industry
- Website
- https://www.takeda.com/fi-fi
- Takeda
- Takeda GmbH
- Publicly traded (proxy)
- No
- Listing at source
- Listed
- Wikidata ID
- Q11875370
Related records
Trials (1,296)
- 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
- 36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Sodium Risedronate 75 mg Tablets
- 90Second IBD for the Improvement of Self Efficacy and Quality of Life in Inflammatory Bowel Disease Patients
- A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)
- A Bioequivalence (BE) Study of TAK-438 Orally Disintegrating (OD) Tablet
- A Bioequivalence Study of TAK-536 Pediatric Formulation
- A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets
- A Chart Review Study of Adults With Advanced NSCLC
- A Clinical Trial With Intranasal Fentanyl in Cancer Patients With Breakthrough Pain
- A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults
- A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin
- A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers
- A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)
- A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression
- A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency
- A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322
- A First-In-Human Study of TAK-004 in Healthy Adults
- A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- A Food Effect Study of TAK-385 Final Formulation